Fig. 5: CDH17 x GUCY2C BsADC shows promising efficacy and safety in mouse models. | Cell Death Discovery

Fig. 5: CDH17 x GUCY2C BsADC shows promising efficacy and safety in mouse models.

From: Development of a bispecific CDH17-GUCY2C ADC bearing the ferroptosis inducer RSL3 for the treatment of colorectal cancer

Fig. 5

A The anti-tumor activity of CDH17 x GUCY2C BsADC in SW1463 and LS1034 xenograft models. Corresponding cancer cells were injected subcutaneously into 7-week-old female immunodeficient mice (5 mice per group) at 5 × 106 cells per mouse, and CDH17-ADC (1 mg/kg), GUCY2C-ADC (1 mg/kg), and BsADC (1 mg/kg) were intravenously administered when the tumor volume of the mice reached a volume of approximately 100–200 mm3. Tumor volumes were measured. The relative levels of MDA (B) and 4-HNE (C) in tumor tissues were measured. D Stability of CDH17 x GUCY2C BsADC in human serum. The serum stability of CDH17 x GUCY2C BsADC was evaluated in PHS over a period of 10 days. The concentrations of both total antibody and conjugated antibody were monitored at various time points. E 7-week-old female hCDH17/hGUCY2 double-humanized BALB/c mice were intravenously injected with PBS or CDH17 × GUCY2C BsADC (1 mg/kg), once every 5 days for a total of 7 injections. The blood chemistry parameters (ALT, left, AST, right) 1 day after the last injection. Data are presented as mean values ± SD. F Representative images of H&E stained the heart, liver, spleen, lung, and kidney tissues of the mice (Scale bar: 100 μm). **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.

Back to article page